Resources
44 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 9/25/2023 (updated 3/27/2024)
The Bureau of Justice Assistance’s (BJA) Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) has provided events and resources throughout September 2023 for National Recovery Month.
Posted 9/8/2023 (updated 3/26/2024)
September 2023 is National Recovery Month and HRSA’s Office of Women’s Health has a toolkit to support organizations and health care providers that care for women living with opioid use disorder (OUD). The toolkit provides strategies to engage women with OUD, care coordination for support, and other resources.
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/31/2023 (updated 3/26/2024)
In this webinar, the presenters discussed these numerous factors affecting social determinants of health (SDOH) and health outcomes, particularly in these communities, and strategies to address them.
Posted 7/31/2023 (updated 3/26/2024)
This presentation will cover health equity regarding rural American Indian and Alaska Native (AI/AN) communities' prevention and treatment efforts to address substance use disorder (SUD), including the need for contingency management for stimulants.
Posted 2/1/2023 (updated 3/27/2024)
This study looks at how common the presence of alcohol is in opioid overdose deaths. While there are "waves" of the opioid crisis, the authors studied how alcohol affect individuals in this fourth wave as it is characterized by opioid-stimulant polysubstance use.
Posted 9/7/2022 (updated 3/27/2024)
During this webinar, Claudia Jasso, Chief Development Officer for RCORP Implementation grantee, Amistades, Inc. and Janet Ojeda, JBS International Technical Expert Lead will present an overview of the unique cultural context, core beliefs, and value systems that should be at the heart of understanding and engaging with Latino populations. Presenters will discuss how racial inequity, assimilation, risk factors, and historical and immigration trauma have created a landscape where there is a critical need for person centered, culturally respectful and relevant mental health and SUD/OUD supports and service delivery for Latino people. All RCORP grantees, consortium members, and key community partners are welcome to attend.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.
Posted 7/25/2022 (updated 3/27/2024)
The interactive graphics allow readers to explore how the crisis of overdose deaths involving opioid use has not only grown in magnitude since 2000, but has also changed in character.